Abivax Stock: Shares Cross the 112 Euro Mark Driven by Sustained Bullish Momentum
Abivax stock is trading at 112.60 euros this Friday morning, up 2.36% from the previous day. The French biotech company, specializing in chronic inflammatory diseases, has shown an impressive trajectory over the year with a growth of nearly 1,586%. The stock is now trading above its main technical benchmarks, just weeks away from the release of its annual 2025 results.
Breaking Resistance Levels
At a price of 112.60 euros, Abivax has surpassed the resistance threshold identified at 110.40 euros, a signal usually interpreted as an opening towards new price levels. The stock is also significantly above its 50-day moving average (104.68 euros), an indicator that reflects the medium-term trend: a positive gap of this magnitude indicates a buying momentum established over several weeks. However, the Relative Strength Index (RSI), which measures the intensity of recent movements, stands at 77, above the threshold of 70 generally associated with an overbought zone. This level indicates that the stock has experienced a rapid acceleration, with a gain of 8.27% over seven days and 16.32% over three months. The major support is at 93.70 euros, representing a gap of more than 16% from the current price, illustrating the magnitude of the recent bullish movement.
Key Financial Milestone Ahead
The next major financial event for Abivax is scheduled for March 23, 2026, the date of the publication of the 2025 annual results. This deadline is particularly significant for the company, whose exceptional stock market performance over the past twelve months — the stock was trading at approximately 6.68 euros a year ago — largely rests on the clinical advancements of its therapeutic portfolio. The monthly volatility of the stock remains contained at 11.68%, while its beta of 0.38 indicates a relatively low sensitivity to general market fluctuations. Abivax thus operates according to dynamics largely specific to its sector fundamentals and specific catalysts. The financial calendar then schedules the communication of the first quarter 2026 results on June 1, followed by the semi-annual accounts on September 14. These publications will mark the coming months and serve as checkpoints to assess the operational trajectory of the biotech.
